From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases - University of Regensburg Publication Server

URN to cite this document:: urn:nbn:de:bvb:355-epub-581533
DOI to cite this document:: 10.5283/epub.58153

Knoedler, Leonard

; Huelsboemer, Lioba ; Hollmann, Katharina ; Alfertshofer, Michael ; Herfeld, Konstantin ; Hosseini, Helia ; Boroumand, Sam ; Stoegner, Viola A. ; Safi, Ali-Farid ; Perl, Markus ; Knoedler, Samuel

; Pomahac, Bohdan ; Kauke-Navarro, Martin

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 23 Apr 2024 16:29

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Malignancies represent a persisting worldwide health burden. Tumor treatment is commonly based on surgical and/or non-surgical therapies. In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhibitors (ICI) have been successfully incorporated into standard treatment algorithms. Such emerging therapy concepts have demonstrated ...